Nova Eye Medical Past Earnings Performance
Past criteria checks 0/6
Nova Eye Medical's earnings have been declining at an average annual rate of -10.6%, while the Medical Equipment industry saw earnings growing at 18.4% annually. Revenues have been growing at an average rate of 14.6% per year.
Key information
-10.56%
Earnings growth rate
-3.25%
EPS growth rate
| Medical Equipment Industry Growth | 5.82% |
| Revenue growth rate | 14.60% |
| Return on equity | -49.26% |
| Net Margin | -32.78% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
US And European Market Expansion Will Unlock New Opportunities
Record sales growth in the U.S. and strategic geographic expansion are driving revenue and market share growth, especially in the Glaucoma division.Nova Eye Medical Limited's (ASX:EYE) Shares Leap 40% Yet They're Still Not Telling The Full Story
May 07
Nova Eye Medical Limited (ASX:EYE) Stock's 30% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Mar 05Nova Eye Medical Limited (ASX:EYE) Stock Rockets 29% But Many Are Still Ignoring The Company
Jan 11We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth
Nov 04Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%
Sep 22Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)
Aug 06Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward
Apr 18Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?
Mar 26News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts
Jan 19Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce
Dec 27We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate
Sep 03Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified
Apr 17Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?
Dec 16We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully
Aug 27Revenue & Expenses Breakdown
How Nova Eye Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 26 | -9 | 25 | 0 |
| 30 Sep 24 | 25 | -9 | 24 | 0 |
| 30 Jun 24 | 23 | -9 | 23 | 0 |
| 31 Mar 24 | 21 | -12 | 20 | 1 |
| 31 Dec 23 | 19 | -14 | 19 | 1 |
| 30 Sep 23 | 18 | -15 | 20 | 1 |
| 30 Jun 23 | 17 | -15 | 22 | 0 |
| 31 Mar 23 | 16 | -13 | 21 | 0 |
| 31 Dec 22 | 15 | -11 | 21 | 0 |
| 30 Sep 22 | 14 | -9 | 19 | 0 |
| 30 Jun 22 | 13 | -7 | 17 | 0 |
| 31 Mar 22 | 13 | -7 | 16 | 0 |
| 31 Dec 21 | 13 | -6 | 15 | 0 |
| 30 Sep 21 | 13 | -5 | 14 | 0 |
| 30 Jun 21 | 13 | -4 | 13 | 0 |
| 31 Dec 20 | 12 | -9 | 12 | 0 |
| 30 Sep 20 | 13 | -10 | 13 | 0 |
| 30 Jun 20 | 13 | -10 | 14 | 0 |
| 31 Dec 19 | 16 | -6 | 16 | 0 |
| 30 Sep 19 | 16 | -6 | 17 | 0 |
| 30 Jun 19 | 16 | -7 | 18 | 0 |
| 31 Mar 19 | 48 | -7 | 34 | 1 |
| 31 Dec 18 | 49 | -6 | 34 | 1 |
| 30 Sep 18 | 64 | -6 | 37 | 1 |
| 30 Jun 18 | 79 | -5 | 41 | 1 |
| 31 Mar 18 | 77 | -5 | 36 | 1 |
| 31 Dec 17 | 75 | -5 | 32 | 1 |
| 30 Sep 17 | 73 | -3 | 31 | 1 |
| 30 Jun 17 | 72 | -1 | 29 | 1 |
| 31 Mar 17 | 72 | 1 | 28 | 1 |
| 31 Dec 16 | 73 | 3 | 27 | 1 |
| 30 Sep 16 | 73 | 3 | 26 | 1 |
| 30 Jun 16 | 73 | 3 | 26 | 1 |
| 31 Mar 16 | 70 | 3 | 24 | 1 |
| 31 Dec 15 | 67 | 2 | 22 | 1 |
| 30 Sep 15 | 65 | 2 | 22 | 1 |
| 30 Jun 15 | 63 | 2 | 21 | 1 |
| 31 Mar 15 | 61 | 1 | 20 | 1 |
| 31 Dec 14 | 59 | 1 | 19 | 1 |
| 30 Sep 14 | 57 | 1 | 18 | 1 |
| 30 Jun 14 | 54 | 1 | 17 | 1 |
Quality Earnings: EYE is currently unprofitable.
Growing Profit Margin: EYE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EYE is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare EYE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (19.6%).
Return on Equity
High ROE: EYE has a negative Return on Equity (-49.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 11:27 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nova Eye Medical Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Michael Youlden | MST Financial Services Pty Limited |
| Robin Morgan | Taylor Collison Limited |